Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma
Public ClinicalTrials.gov record NCT00003958. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomized Study of Vincristine, Actinomycin-D, and Cyclophosphamide (VAC) Versus VAC Alternating With Vincristine, Topotecan and Cyclophosphamide for Patients With Intermediate Risk Rhabdomyosarcoma
Study identification
- NCT ID
- NCT00003958
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Children's Oncology Group
- Network
- Enrollment
- 702 participants
Conditions and interventions
Conditions
- Adult Malignant Mesenchymoma
- Adult Rhabdomyosarcoma
- Alveolar Childhood Rhabdomyosarcoma
- Childhood Malignant Mesenchymoma
- Embryonal Childhood Rhabdomyosarcoma
- Embryonal-botryoid Childhood Rhabdomyosarcoma
- Nonmetastatic Childhood Soft Tissue Sarcoma
- Previously Untreated Childhood Rhabdomyosarcoma
- Stage I Adult Soft Tissue Sarcoma
- Stage II Adult Soft Tissue Sarcoma
- Stage III Adult Soft Tissue Sarcoma
Interventions
- cyclophosphamide Drug
- dactinomycin Biological
- filgrastim Biological
- laboratory biomarker analysis Other
- radiation therapy Radiation
- sargramostim Biological
- therapeutic conventional surgery Procedure
- topotecan hydrochloride Drug
- vincristine sulfate Drug
Drug · Biological · Other + 2 more
Eligibility (public fields only)
- Age range
- Up to 49 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2002
- Primary completion
- Sep 30, 2007
- Completion
- Not listed
- Last update posted
- Jun 16, 2013
Started 2002
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Children's Oncology Group | Arcadia | California | 91006-3776 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00003958, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 16, 2013 · Synced May 15, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00003958 live on ClinicalTrials.gov.